All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Dengue virus (DENV) is a mosquito-borne arbovirus that is transmitted primarily by the species *Aedes aegypti*. The global burden of DENV has grown dramatically in the last few decades \[[@pntd.0004941.ref001], [@pntd.0004941.ref002]\]. We now expect approximately one hundred million clinically recognized cases of disease each year. Targeted therapeutics do not exist. Fortunately, conventional vaccines are in development and regulatory approval has been granted in a few countries. Development of a conventional DENV vaccine has been difficult due to the co-circulation of four serotypes \[[@pntd.0004941.ref003], [@pntd.0004941.ref004]\]. It is critical that conventional vaccines elicit robust antibody titers to avoid antibody-dependent enhancement, which occurs during a sub-neutralizing response. It is theoretically possible to target mosquito saliva or midgut proteins to block either transmission or acquisition of DENV \[[@pntd.0004941.ref003], [@pntd.0004941.ref005], [@pntd.0004941.ref006]\]. This strategy would not be subject to antibody-dependent enhancement or viral genetic drift.

*Ae*. *aegypti* saliva contains over one hundred unique proteins that have been classified as D7 proteins, phosphatidylethanolamine binding proteins, odorant and juvenile hormone binding proteins, serpins and other protease inhibitors, a sialokinin vasodilator, nucleotidases, serine proteases, sugar digestion related proteins and other enzymes, lectins, angiopoietins, anti-microbial proteins and peptides, mucins and peritrophins, antigen 5 proteins, and many more proteins of unknown function \[[@pntd.0004941.ref007]--[@pntd.0004941.ref011]\]. Functional data is not available for the majority of these proteins, although it is expected that the saliva of all hematophagous arthropods have anti-coagulant, anti-platelet, and vasodilatory activities. It is also likely that saliva proteins serve to reduce host inflammation and prevent infection.

In addition to the normal physiological roles of hematophagous arthropod saliva, many vector-borne microorganisms have enhanced fitness in the presence of arthropod saliva. Arthropod saliva can enhance infectivity of West Nile virus, DENV, Rift Valley fever virus, and Powassan virus, among others \[[@pntd.0004941.ref005], [@pntd.0004941.ref012]--[@pntd.0004941.ref018]\]. The exact mechanism of saliva-mediated infectivity enhancement is not known, although prior literature suggests that saliva proteins may locally modify the immune system in favor of arbovirus replication and/or stimulate dissemination by enhancing migration of target cells to draining lymph nodes \[[@pntd.0004941.ref003]\]. Interestingly, individual saliva components can have inhibitory activities against arbovirus infection. For instance, the collagen-binding protein aegyptin decreased DENV infection *in vivo* \[[@pntd.0004941.ref019]\]. Additionally, previous literature showed that vaccination of mice with a recombinant D7 protein from *Culex spp*. enhanced mortality in a West Nile virus mouse model, suggesting that D7 protein may be inhibitory *in vivo* \[[@pntd.0004941.ref020]\]. Structural studies suggest that D7 proteins can simultaneously bind biogenic amines and cysteinyl leukotrienes, which is likely involved in preventing the host inflammatory response \[[@pntd.0004941.ref021], [@pntd.0004941.ref022]\]. Prevention of the host inflammatory response may reduce influx or activation of target cells.

Our previous work relied on high performance liquid chromatography (HPLC) to fractionate *Ae*. *aegypti* salivary gland extracts (SGEs) \[[@pntd.0004941.ref005]\]. HPLC fractions were tested to see if they had virus enhancing or blocking activities *in vitro*. Here, we identified a number of fractions that inhibited DENV cell binding and then pooled these fractions for downstream tandem liquid chromatography tandem mass spectrometry (LC+MS/MS) analysis. D7 proteins were the most abundant proteins in the inhibitory fractions. We synthesized a recombinant D7 protein and found that it inhibited DENV infection *in vitro* and *in vivo*. Additionally, the D7 protein interacted directly with DENV virions and recombinant envelope protein. These data support a model whereby D7 proteins inhibit DENV infection through two independent mechanisms: (i) direct binding and neutralization of DENV virions, and (ii) inhibition of immune cell infiltration or activation, which reduces the number of permissive target cells. Characterization of virus-vector-host interactions at the transmission interface will further development of arthropod-based therapeutics and transmission-blocking vaccines.

Methods {#sec002}
=======

Mosquito rearing and saliva material collection {#sec003}
-----------------------------------------------

*Aedes aegypti* were provided by staff at the Connecticut Agricultural Experiment Station. Mosquitoes were maintained in a sugar solution at 27°C and 80% humidity according to standard rearing procedures. Salivary glands and saliva were isolated as described previously \[[@pntd.0004941.ref005]\]. Salivary gland extracts were prepared by placing 100 salivary glands in 100 μl sterile phosphate-buffered saline (PBS), freeze-thawing by placing on dry ice three times, and then removing insoluble debris by centrifugation at 5,000 × *g* for 10 min. Saliva was isolated using the immersion oil technique.

Cell culture and virus stocks {#sec004}
-----------------------------

Mouse embryonic fibroblasts (MEFs) and a human monocyte-like (U937) cell line from the American Type Culture Collection were maintained in Dulbecco\'s modified Eagle medium (DMEM) containing 10% fetal bovine serum and antibiotics at 37°C with 5% CO~2~ (Gibco). C6/36 cells were maintained in DMEM containing 10% fetal bovine serum, tryptose phosphate, and antibiotics at 30°C. DENV2 was passaged in C6/36 cells. DENV2 New Guinea C strain was obtained from the Connecticut Agricultural Experiment Station and C6/36 cells were a kind gift from Erol Fikrig. Approximately 1 × 10^5^ genome equivalents (GE) were used for *in vitro* infections of MEFs and U937 cells.

HPLC fractionation and LC+MS/MS {#sec005}
-------------------------------

One hundred salivary glands were dissected from female *Ae*. *aegypti* and placed in 100 μl PBS. The sample was freeze-thawed three times at −80°C, and insoluble debris was pelleted by centrifugation at 5,000 × *g* for 10 min. The supernatant was reserved. SGE was either processed directly for LC+MS/MS analysis or fractionated by high-performance liquid chromatography (HPLC) on a nonporous reverse-phase column with a TFA buffer system into 80 100-μl fractions. Ten μl of each fraction was diluted into 90 μl PBS and used as SGE treatments for *in vitro* SGE-mediated cell binding assays as stated below. The remaining 90 μl from inhibitory fractions 31--49 were pooled and submitted for liquid chromatography tandem mass spectrometry (LC+MS/MS) analysis.

Proteins were digested with trypsin and analyzed using LC+MS/MS on a Thermo Scientific LTQ-Orbitrap XL mass spectrometer using Waters nanoACQUITY ultra-high-pressure liquid chromatographs (UPLC) for peptide separation. MS/MS spectra were searched in-house using the Mascot algorithm for uninterpreted MS/MS spectra after using the Mascot Distiller program to generate Mascot-compatible files. An *A*. *aegypti* database was used for searching. The Keck Biotechnology Resource at Yale University performed both HPLC and LC+MS/MS.

*In vitro* cell binding assay {#sec006}
-----------------------------

MEFs were seeded at 25,000 cells/well in 48-well plates and grown to approximately 70% confluence overnight. Medium was aspirated, and cells were washed with PBS. Ten μl of HPLC fractions were diluted in a total volume of 100 μl PBS and inoculated into cells at room temperature for 10 min. Saliva material was removed, and then Approximately 1 × 10^5^ GE of DENV2 was inoculated into cells in a total volume of 500 μl for 1 h at 37°C. Unbound virus was then removed, and fresh medium was added. Infections progressed for up to 18 h. Total RNA was extracted using RNeasy kits (Qiagen).

For analysis of relative DENV vRNA, total RNA was harvested using RNeasy kits (Qiagen). Amplification of both the viral target and reference gene target was performed using a duplex format in 0.2-ml, 96-well PCR plates (Bio-Rad) with a total reaction volume of 25 μl. Reverse transcription and quantitative PCR (RT-qPCR) were performed in the same closed tube with 250 ng of total RNA per reaction using the Quantitect RT-PCR kit (Qiagen).

All primers were used at a final concentration of 4 μM and were synthesized by the Keck Facility at Yale University. DENV2 vRNA was amplified using F 5' CCACTGCCTCTGGAAAACTC 3' and R 5' GTACCAGCACCCATCCTCAC 3' primers. Primers were developed using Gene Link Software (OligoAnalyzer 1.2 and OligoExplorer 1.2). All RT-qPCRs were performed using an iQ5 machine (Bio-Rad). Cycling conditions were 50°C for 30 min (reverse transcription) and 95°C for 15 min, followed by 42 cycles of 94°C for 15 s and 54.5°C for 1 min. Relative quantities of viral target cDNA were determined using REST software.

Cloning {#sec007}
-------

*Ae*. *aegypti* total cellular RNA was converted to cDNA using random primers and the Superscript III First-Strand Synthesis System (ThermoFisher). Long form D7 protein (AAEL006424) was amplified using F 5' GGAGGTACCGATGAAGCTGCCTCTATTACTCGCAATAGTTAC 3' and R 5' GGAGCGGCCGCAATTGTGGACACTGTTTACCGTCG 3' primers and cloned into the pMT/BiP/V5-His A plasmid via BamHI and NotI restriction sites. pMT/BiP/D7/V5-His A and pCoHygro plasmids were transfected into S2 cells using the calcium phosphate method according to manufacturers' instructions (ThermoFischer) and a stable cell line was generated through hygromycin selection. D7 synthesis and secretion was induced by treating cells with copper sulfate according to manufacturer's instructions (ThermoFisher). D7 expression was confirmed by Coomassie Blue gel staining and Western blot using an anti-6 His antibody. Supernatants were also harvested from uninduced S2 cell supernatants and used as negative controls.

*In vitro* infectivity assay {#sec008}
----------------------------

D7 protein was purified using HisPur Cobalt Spin Columns (Thermo Scientific/Pierce, MA) according to manufacturer instructions. There were a total of 3 washes and 3 elutions. Samples were stored at -80°C until use. The U937 cell line (ATCC, VA) was used for the *in vitro* infection studies. The cells were grown at 37°C and 5% CO2 in DMEM supplemented with 10% fetal bovine serum (Gemini, CA), and 1% penicillin-streptomycin. D7 was used in 1/10, 1/100, and 1/1000 dilutions in complete media for final concentrations of 8, 0.8, and 0.08 ng/mL, respectively. Dilutions were added for pretreatment of cells in a total volume of 250 μL. Cells were then incubated for 1 hour at 37°C and then DENV was added to cells at a multiplicity of infection (MOI) of 1.0. For simultaneous treatments, ten-fold dilutions of D7 were mixed with DENV2 and these mixtures were pre-incubated for 1 hour at 37°C. D7-DENV2 mixtures were then inoculated onto cells. Unbound virions were removed by washing after 1 hour and then cells were incubated for 24 hours at 37°C. RNA was isolated from cells and qRT-PCR performed as described above. DENV2 vRNA was amplified using Forward: 5' CAG ATC TCT GAT GAA TAA CCA ACG 3' and Reverse: 5' CAT TCC AAG TGA GAA TCT CTT TGT CA 3' primers. Human B2M RNA was amplified using Forward: 5' CTC CGT GGC CTT AGC TGT G 3' and Reverse: 5' TTT GGA GTA CGC TGG ATA GCC T 3' primers.

Ethics statement {#sec009}
----------------

Animals were maintained and procedures were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Research Council. Protocol 14051879 was approved by the University of Pittsburgh\'s IACUC committee. Approved euthanasia criteria were based on weight loss and morbidity.

*In vivo* infectivity assay {#sec010}
---------------------------

Mice deficient in receptors for type I and type II interferons, (IFNAGR^-/-^, AGB6) were bred under specific pathogen-free conditions. Groups of 4-5-week-old, age-matched, mixed-sex AGB6 mice were inoculated subcutaneously into both rear footpads with 20 μl containing either 10^7^ genome equivalents (GE) of either DENV2 alone or DENV2 plus recombinant D7 protein. DENV2 alone samples contained purified S2 cell supernatant without D7 protein as a vehicle control. Forty-eight hours post-infection, mice were euthanized and left and right foot pads and left and right popliteal draining lymph nodes (DLN) were collected independently. Total RNA was extracted using an RNeasy kit (Qiagen). qRT-PCR was performed by adding equal amounts of RNA into each reaction and data were normalized to the actin reference gene. Mouse actin RNA was amplified using Forward: 5' GGC TGT ATT CCC CTC CAT CG 3' and Reverse: 5' CCA GTT GGT AAC AAT GCC ATG T 3' primers. Amplification of targets were performed using a duplex format in 0.2 ml, 96-well PCR plates (BIO-RAD) with a total reaction volume of 25 μl. Reverse transcription and quantitative PCR were performed in the same closed tube with 100 ng of total RNA per reaction using the Quantitect RT-PCR Kit (Qiagen).

Salivary gland extract-DENV virion binding assay {#sec011}
------------------------------------------------

Seventy μg of anti-dengue virus type II antibody, clone 3H5-1 (Millipore) was covalently coupled to 25 μL amine-active resin according to the Pierce Co-Immunoprecipitation Kit manual (ThermoFisher Scientific). One hundred μg purified, formaldehyde-inactivated dengue virus type 2 virions (Microbix) was then mixed with 100 *Ae*. *aegypti* salivary gland equivalents and added to the antibody-containing resin with gentle end-over-end mixing for 2 hr at 4°C. Unbound proteins were washed away and bound proteins were eluted in a final volume of 50 μL. The experimental details are described in the Pierce Co-Immunoprecipitation Kit manual. Eluted proteins were identified by LC+MS/MS analysis as stated above.

Enzyme-linked immunosorbent assay {#sec012}
---------------------------------

High binding 96-well plates were coated overnight at 4°C with a 1:1 dilution of D7 or matrix metalloproteinase protein (MMP; AAEL003012) in coating buffer (R&D systems) for a 0.01mg/mL final concentration. The next day, plates were rinsed twice with PBS and blocked with blocking buffer (1% BSA in 1XPBST) for 1 h at 37. Plates were incubated with 80μL of DENV 2 strain 186881 (2x10^5^ p.f.u) or recombinant DENV Envelope protein (1μg/mL) (L2 Diagnostics, CT) overnight at 4°C. Plates were washed three times with buffer (1X PBST+ 0.01% Tween 20) and incubated with a 1:250 dilution of primary antibody for 1h at 37°C: mouse anti-DENV2 antibody (MAB10226, Millipore) to detect virus and mouse anti-E antibody (MA1-71251, Pierce) to detect envelope protein. After washing plates three times, wells were incubated with 100 μL of a 1:1000 dilution of anti-mouse IgG, HRP-linked antibody (Cell Signaling Technologies) and washed after 1h of incubation at 37°C. Reaction was visualized after incubating with 80 μL of TMB. After 3min the reaction was stopped with stop solution (2M Sulfuric acid) and plates were read at 450nm in a Synergy HT plate reader (Biotek Instruments Inc., VT).

Results {#sec013}
=======

Identification of D7 proteins in inhibitory salivary gland extract high performance liquid chromatography fractions {#sec014}
-------------------------------------------------------------------------------------------------------------------

We previously showed that pre-treatment of mouse embryonic fibroblasts (MEFs) with salivary gland extract (SGE) increased DENV cell binding \[[@pntd.0004941.ref005]\]. Reverse phase HPLC fractionation and LC+MS/MS analysis was then used to identify fractions of *Ae*. *aegypti* salivary gland extract (SGE) that increased DENV vRNA levels associated with mouse embryonic fibroblasts (MEFs)\[[@pntd.0004941.ref005]\]. During this analysis, we also noted that a cluster of HPLC fractions (i.e., 31--49) inhibited DENV infection ([Fig 1](#pntd.0004941.g001){ref-type="fig"}). These fractions were pooled and submitted for LC+MS/MS analysis and searched against the NCBI *Ae*. *aegypti* database to identify the most abundant proteins. Multiple proteins were identified with high score values, although long forms of the D7 protein family were the most prevalent ([Table 1](#pntd.0004941.t001){ref-type="table"}). A number of these proteins were not predicted as secreted proteins that would be present in saliva. To validate the proteins that are present in saliva and may play a role at the virus-vector-host interface, saliva was harvested from one hundred *Ae*. *aegypti* using the immersion oil technique \[[@pntd.0004941.ref023]\]. Soluble proteins were extracted from immersion oil using phosphate buffered saline and the sample was submitted for LC+MS/MS analysis. We confirmed that 7 proteins in the inhibitory fraction are also present in saliva (Tables [1](#pntd.0004941.t001){ref-type="table"} and [2](#pntd.0004941.t002){ref-type="table"}). Three of these proteins were either long or short form D7 proteins.

![Impact of HPLC-fractionated *Ae*. *aegypti* salivary gland extract on DENV2 cell binding.\
Individual HPLC fractions were used to pre-treat mouse embryonic fibroblasts prior to inoculation with DENV2. Total RNA was harvested and qRT-PCR was performed 18 hours post-infection. Relative levels of DENV2 were normalized to GAPDH. An untreated control was set to 1.0 and was placed on the far left of the graph (black bar).](pntd.0004941.g001){#pntd.0004941.g001}

10.1371/journal.pntd.0004941.t001

###### LC+MS/MS hits from pooled inhibitory HPLC SGE fractions.

![](pntd.0004941.t001){#pntd.0004941.t001g}

  Identifier   Comments                                      Score   Present in saliva
  ------------ --------------------------------------------- ------- -------------------
  AAEL006424   D7 protein long                               2221    Yes
  AAEL006417   D7 protein long                               2100    Yes
  AAEL010235   30 kDa salivary protein                       1852    Yes
  AAEL002761   Tropomyosin                                   1023    No
  AAEL011949   Transferrin                                   984     No
  AAEL006333   Apyrase                                       933     Yes
  AAEL006096   Gelsolin                                      898     No
  AAEL001005   Calreticulin                                  725     No
  AAEL010228   30 kDa allergen-like protein                  710     Yes
  AAEL006423   D7 protein short                              707     Yes
  AAEL003566   Galactose-specific C-type lectin              688     No
  AAEL000533   Antifreeze protein                            650     No
  AAEL012897   Mitochondrial aconitase                       621     No
  AAEL006406   Hypothetical protein                          603     No
  AAEL009852   14.5 kDa salivary protein                     586     No
  AAEL002539   Calponin/transgelin                           579     No
  AAEL002417   Troponin T isoform 1                          564     No
  AAEL013528   Peroxiredoxin                                 467     No
  AAEL007394   Hypothetical protein                          432     No
  AAEL010242   8.7 kDa salivary protein                      403     No
  AAEL003957   Hypothetical protein                          387     No
  AAEL003600   34 kDa salivary protein                       382     Yes
  AAEL013279   Cyclophilin                                   344     No
  AAEL017096   Translation elongation factor EF-1 alpha/Tu   299     No
  AAEL013407   Hypothetical protein                          293     No
  AAEL017096   Lysozyme                                      280     No

10.1371/journal.pntd.0004941.t002

###### LC+MS/MS hits from *Aedes aegypti* saliva.

![](pntd.0004941.t002){#pntd.0004941.t002g}

  Identifier   Comments                                          Score
  ------------ ------------------------------------------------- -------
  AAEL000732   62 kDa secreted protein                           1227
  AAEL003182   Serine protease inhibitor (serpin)                738
  AAEL005672   Adenosine deaminase                               721
  AAEL006417   D7 protein long                                   652
  AAEL006347   Apyrase precursor                                 648
  AAEL003600   34 kDa salivary protein                           535
  AAEL003601   34 kDa salivary protein                           430
  AAEL002704   Serine protease inhibitor (serpin)                361
  AAEL006424   D7 protein long                                   344
  AAEL010235   30 kDa salivary gland protein                     336
  AAEL009081   56.5 kDa salivary protein                         329
  AAEL003053   Allergen                                          302
  AAEL006333   Salivary apyrase                                  286
  AAEL000748   62 kDa secreted protein                           270
  AAEL006485   Inosine-uridine preferring nucleoside hydrolase   210
  AAEL010228   30 kDa allergen-like protein                      199
  AAEL003100   Salivary mucin                                    181
  AAEL000793   Venom allergen                                    181
  AAEL005766   Fructose-bisphosphate aldolase                    148
  AAEL011197   Actin                                             132
  AAEL003107   Hypothetical                                      123
  AAEL009992   Hypothetical                                      120
  AAEL006423   D7 protein short                                  107
  AAEL000490   Histone H4                                        82
  AAEL009955   Vitellogenin-like protein                         73
  AAEL006511   Ubiquitin                                         71
  AAEL009993   SGS1                                              68

In a separate experiment, we sought to elucidate proteins that are upregulated in salivary glands during DENV2 infection. *Ae*. *aegypti* were either mock or infected with DENV2 via blood feeding using an artificial membrane. Twenty salivary glands were isolated from each group of mosquitoes 14 dpi and equal amounts of protein were loaded on to an SDS-PAGE gel for one-dimensional gel electrophoresis. Gels were stained with Coomassie Blue. Multiple bands were different between mock and DENV2 lanes, but one band appeared significantly darker in the DENV2-infected lane ([Fig 2A](#pntd.0004941.g002){ref-type="fig"}). The band from the DENV2-infected lane was excised and submitted for mass spectrometry. Only four unique *Ae*. *aegypti* proteins were detected, which included tropomyosin, two long form D7 proteins, and a 34 kDa salivary protein ([Fig 2B](#pntd.0004941.g002){ref-type="fig"}). We confirmed that both long and short form D7 proteins and the 34 kDa salivary protein are upregulated in *Ae*. *aegypti* salivary glands at the transcriptional level during DENV2 infection by assessing previously published RNA Seq data ([Table 3](#pntd.0004941.t003){ref-type="table"}) \[[@pntd.0004941.ref011]\].

![Identification of upregulated *Ae*. *aegypti* salivary gland proteins during DENV2 infection.\
(A) Section of a Coomassie Blue stained gel containing approximately 1 μg salivary gland extracts from mock-infected and DENV2-infected *Ae*. *aegypti*. A single band was more intense during DENV2 infection. (B) Proteins identified within the DENV2-specific band as shown above by mass spectrometry.](pntd.0004941.g002){#pntd.0004941.g002}

10.1371/journal.pntd.0004941.t003

###### Gene accumulation levels in FPKM in mock and DENV2-infected *Ae*. *aegypti* salivary glands 14 days post-infection.

![](pntd.0004941.t003){#pntd.0004941.t003g}

  Identifier   Comments                    Mock     DENV2
  ------------ --------------------------- -------- --------
  AAEL006417   D7 protein long             5,869    11,411
  AAEL006424   D7 protein long             13,440   28,913
  AAEL006423   D7 protein short            2,828    7,982
  AAEL006408   D7 protein short            1,960    2,336
  AAEL006406   D7 protein short            4,785    7,916
  AAEL007394   D7 protein short            1,529    6,718
  AAEL003600   34 kDa salivary protein     6,287    14,361
  AAEL002759   Tropomyosin, invertebrate   36       11

Recombinant D7 protein inhibits dengue virus *in vitro* and *in vivo* {#sec015}
---------------------------------------------------------------------

*Ae*. *aegypti* D7 proteins are multifunctional and have been shown to bind to cysteinyl leukotrienes (cysLT) and biogenic amines with high affinity. Based on the discovery of D7 proteins in inhibitory HPLC fractions, and of increased D7 protein expression in DENV2-infected salivary glands, we hypothesized that D7 proteins may bind to additional substrates with varying affinities, and that these interactions inhibit DENV cell binding and infectivity. To test this hypothesis, a recombinant D7 long form protein (AAEL006424) was produced in S2 cells and harvested from the supernatant at a concentration of 80 ng/mL ([Fig 3A and 3B](#pntd.0004941.g003){ref-type="fig"}). We determined if D7 protein was toxic to cells by incubating ten-fold dilutions of D7 protein with monocyte-like U937 cells for 24 hours followed by analysis using Promega's CellTox Green Cytotoxicity Assay. This assay measures membrane integrity that occurs as a result of cell death. Both positive and negative controls were included. None of the dilutions tested were toxic to U937 cells at the time point tested ([Fig 4A](#pntd.0004941.g004){ref-type="fig"}).

![Characterization of recombinant D7 protein.\
(A) Coomassie Blue gel stain of crude S2 cell lysate containing recombinant D7 protein and D7 protein after purification using a HisPur Cobalt Spin Column. (B) Western blot of uninduced (---) and induced (D7) S2 cell supernatants using an anti-6 His antibody.](pntd.0004941.g003){#pntd.0004941.g003}

![Recombinant D7 protein inhibits DENV2 infection in U937 cells.\
(A) The Promega CellTox^TM^ Green Cytotoxicity Assay was used to determine the toxicity of ten-fold dilutions of recombinant D7 protein on U937 cells 24 hours post-treatment. (B) U937 cells were either uninfected (UI), infected with DENV2 alone, pre-treated with 10-fold dilutions of recombinant D7 protein followed by DENV2 infection, or co-treated with 10-fold dilutions of recombinant D7 protein with concomitant DENV2 infection. Total RNA was harvested and qRT-PCR was performed 24 hours post-infection. Relative levels of DENV2 were normalized to B2M. (C) U937 cells were either uninfected (UI), infected with DENV2 alone, or infected followed by post-treatment with 10-fold dilutions of recombinant D7 protein. Post-treatment began 24 hpi and lasted 8 hours. Total RNA was harvested and qRT-PCR was performed 48 hours post-infection. Relative levels of DENV2 were normalized to B2M. (D) U937 cells were either uninfected (UI), infected with DENV2 alone, or pre-treated with recombinant Hig-tagged GFP, representing the highest concentration used for D7 protein followed by DENV2 infection. Total RNA was harvested and qRT-PCR was performed 24 hours post-infection. Relative levels of DENV2 were normalized to B2M. Data represent averages of at least 3 independent experiments. Student's t tests were performed to assess statistical significance between groups.](pntd.0004941.g004){#pntd.0004941.g004}

We then tested if D7 protein had antiviral activity *in vitro* by either pre-incubating U937 cells with ten-fold dilutions of recombinant D7 protein for 1 hour at 37°C prior to inoculation with DENV2, or incubating ten-fold dilutions of D7 protein with DENV2 for 1 hour at 37°C prior to co-treatment with D7-DENV2 mixtures. The different treatment strategies were employed to determine if D7 needed to directly interact with virions for activity. Total RNA was extracted 24 hpi and the relative amount of DENV2 vRNA was normalized to a housekeeping gene. Both pre-treatment and co-treatment of recombinant D7 protein and DENV2 significantly reduced DENV2 vRNA levels in U937 cells and there wasn't a statistical difference between these two treatment groups ([Fig 4B](#pntd.0004941.g004){ref-type="fig"}). A post-treatment experiment was also performed to determine if D7 inhibited DENV at an early time point during infection. In this experiment, U937 cells were infected with DENV for 24 hours, followed by an 8 hour treatment with ten-fold dilutions of D7 protein. Total RNA was extracted 48 hpi and the relative amount of DENV2 vRNA was normalized to a housekeeping gene. This treatment strategy did not significantly inhibit DENV infection, suggesting that D7 inhibits DENV at an early time point ([Fig 4C](#pntd.0004941.g004){ref-type="fig"}). We also tested if an irrelevant His-tagged protein could inhibit DENV infection. Recombinant His-tagged GFP was unable to inhibit DENV infection at the highest concentration tested for D7 ([Fig 4D](#pntd.0004941.g004){ref-type="fig"}).

To determine if recombinant D7 can inhibit DENV2 infection *in vivo*, we challenged AGB6 mice with DENV2 with and without D7 protein by subcutaneous footpad inoculation. AGB6 mice were chosen because they are highly permissive to DENV2 infection and were a suitable model for early DENV2 replication and dissemination to draining lymph nodes. Briefly, 2 groups of 4-5-week-old, age-matched, sex-matched mice were inoculated into a single rear footpad with 20 μl containing 1 x 10^7^ genome equivalents, DENV2 alone or in combination with approximately 1 ng recombinant D7 protein. In order to test the impact of D7 treatment on early replication and dissemination, RNA was harvested from footpads and draining lymph nodes 48 hpi and qRT-PCR was used to measure the relative levels of DENV2 normalized to an actin reference gene \[[@pntd.0004941.ref005]\]. D7 protein significantly reduced DENV2 vRNA levels in both the footpads and draining lymph nodes 24 hpi ([Fig 5A and 5B](#pntd.0004941.g005){ref-type="fig"}). DENV2 vRNA amplified at Ct values of 21--24 in footpad samples and 17--19 in draining lymph node samples.

![Recombinant D7 protein inhibits DENV2 infection in AGB6 mice.\
Mice deficient in receptors for type I and type II interferons, (IFNAGR-/-, AGB6) were inoculated subcutaneously into both rear footpads with 20 μl containing either 10^7^ genome equivalents of either DENV2 alone or DENV2 plus recombinant D7 protein. Forty-eight hours post-infection, mice were euthanized and left and right foot pads and left and right popliteal draining lymph nodes (DLN) were collected independently. (A) Total RNA was harvested from footpad tissue and qRT-PCR was performed to assess relative levels of DENV2 vRNA. Relative DENV2 vRNA was normalized to actin gene expression. (B) Total RNA was harvested from DLNs and qRT-PCR was performed to assess relative levels of DENV2 vRNA. Relative DENV2 vRNA was normalized to actin gene expression. 5 mice were present in each group and the data represents a single experiment. Unpaired t tests were performed to assess statistical significance.](pntd.0004941.g005){#pntd.0004941.g005}

Recombinant D7 protein directly interacts with dengue virions and envelope protein {#sec016}
----------------------------------------------------------------------------------

Our results suggest that D7 protein can inhibit DENV2 infection *in vitro* and *in vivo*, although it is unclear how D7 protein mediates its antiviral effect. Pre-treatment of U937 cells with recombinant D7 protein led to a significant decrease in DENV2 infection, suggesting that D7 protein may modulate the host cell. Although, co-treatment of D7 protein with DENV2 appeared to be more effective at preventing cell binding and/or infection of U937 cells. We hypothesized that D7 protein can interact with multiple substrates including proteins at the cell surface and viral proteins. To test this hypothesis, we performed binding assays to determine if D7 protein can bind to DENV virions and envelope protein.

First, anti-DENV2 antibody, clone 3H5-1 was covalently coupled to 25 μL amine-active resin in two separate columns. One hundred μg of purified, formaldehyde-inactivated dengue virus type 2 virions was then mixed with 100 *Ae*. *aegypti* salivary gland equivalents and added to the antibody-containing resin and incubated for 2 hr at 4°C. A negative control column containing anti-DENV2 antibody was also prepared with only 100 salivary gland equivalents. Unbound proteins were washed away and bound proteins were eluted. Eluted proteins were identified by LC+MS/MS analysis. Although Mascot scores were low, 8 proteins were identified that were unique and not in the negative control and three of these were present in saliva (Tables [2](#pntd.0004941.t002){ref-type="table"} and [4](#pntd.0004941.t004){ref-type="table"}). This included the long form D7 protein (AAEL006424). To determine if the proteins we detected were simply correlated with their abundance, we performed LC+MS/MS analysis on *Ae*. *aegypti* salivary gland extracts ([Table 5](#pntd.0004941.t005){ref-type="table"}). Although actin and serine protease inhibitor (serpin) had Mascot scores in the top 3%, Mascot data suggested that the remaining proteins were less abundant, and that our co-immunoprecipitation data did not simply represent the most abundant proteins in salivary gland extracts.

10.1371/journal.pntd.0004941.t004

###### LC+MS/MS hits from SGE/DENV2 binding assay.

![](pntd.0004941.t004){#pntd.0004941.t004g}

  Identifier^a^   Comments                                      Score   Present in saliva
  --------------- --------------------------------------------- ------- -------------------
  AAEL001951      Actin                                         137     No
  AAEL003601      34 kDa salivary protein                       99      Yes
  AAEL005056      Electron transfer flavoprotein beta subunit   94      No
  AAEL003182      Serine protease inhibitor (serpin)            73      Yes
  AAEL012175      F1 ATP synthase alpha subunit                 57      No
  AAEL006424      D7 protein long                               53      Yes
  AAEL013144      Translation initiation factor 3 subunit       49      No
  AAEL010242      8.7 kDa secreted protein                      48      No

^a^ Protein hits represent unique identifiers that were not present in the negative control.

10.1371/journal.pntd.0004941.t005

###### LC+MS/MS hits from *Aedes aegypti* salivary gland extract.

![](pntd.0004941.t005){#pntd.0004941.t005g}

  Identifier   Comment                                                                                     Score
  ------------ ------------------------------------------------------------------------------------------- -------
  AAEL009993   SGS1                                                                                        5240
  AAEL009992   N/A                                                                                         4161
  AAEL002827   ATP synthase beta subunit                                                                   1343
  AAEL000732   62 kDa secreted protein, putative                                                           1238
  AAEL003182   serine protease inhibitor (serpin) homologue---unlikely to be inhibitory                    1056
  AAEL011197   actin                                                                                       1050
  AAEL005961   actin                                                                                       954
  AAEL006347   apyrase precursor                                                                           887
  AAEL001928   actin-1                                                                                     880
  AAEL009955   vitellogenin-like protein                                                                   812
  AAEL000749   angiopoietin-like protein splice variant                                                    798
  AAEL006333   salivary apyrase, putative                                                                  795
  AAEL008787   V-type proton ATPase catalytic subunit A                                                    782
  AAEL000748   62 kDa secreted protein, putative                                                           778
  AAEL001951   actin                                                                                       771
  AAEL005672   adenosine deaminase                                                                         737
  AAEL002851   tubulin beta chain                                                                          731
  AAEL012175   ATP synthase alpha subunit mitochondrial                                                    728
  AAEL009081   56.5 kDa secreted protein, putative                                                         717
  AAEL009185   arginine or creatine kinase                                                                 701
  AAEL005733   myosin heavy chain, nonmuscle or smooth muscle                                              629
  AAEL013739   electron transport oxidoreductase                                                           614
  AAEL006642   tubulin alpha chain                                                                         585
  AAEL003655   N/A                                                                                         580
  AAEL005656   myosin heavy chain, nonmuscle or smooth muscle                                              577
  AAEL009691   carboxylase:pyruvate/acetyl-coa/propionyl-coa                                               576
  AAEL012576   pyruvate kinase                                                                             534
  AAEL010697   3-ketoacyl-coa thiolase, mitochondrial                                                      511
  AAEL004988   phosphoglycerate kinase                                                                     510
  AAEL003053   allergen, putative                                                                          510
  AAEL005766   fructose-bisphosphate aldolase                                                              508
  AAEL002704   serine protease inhibitor (serpin) homologue                                                499
  AAEL003872   translationally-controlled tumor protein homolog (TCTP)                                     467
  AAEL010146   3-hydroxyacyl-coa dehyrogenase                                                              440
  AAEL011288   elongation factor 1 gamma                                                                   432
  AAEL007420   serine protease inhibitor (serpin) homologue---unlikely to be inhibitory                    429
  AAEL003734   aconitase, mitochondrial                                                                    428
  AAEL006485   inosine-uridine preferring nucleoside hydrolase                                             417
  AAEL004338   pyruvate dehydrogenase                                                                      411
  AAEL002542   triosephosphate isomerase                                                                   411
  AAEL001593   glycerol-3-phosphate dehydrogenase                                                          393
  AAEL000951   elongation factor 1-beta2                                                                   375
  AAEL008166   malate dehydrogenase                                                                        372
  AAEL010821   60S acidic ribosomal protein P0                                                             362
  AAEL013614   clathrin heavy chain                                                                        353
  AAEL005515   heterogeneous nuclear ribonucleoprotein                                                     350
  AAEL010235   30 kDa salivary gland allergen Aed a 3 Precursor (Allergen Aed a 3)                         349
  AAEL006582   calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type                         340
  AAEL006719   alpha-amylase I precursor                                                                   339
  AAEL012827   endoplasmin                                                                                 330
  AAEL011584   chaperonin-60kD, ch60                                                                       330
  AAEL011704   heat shock protein                                                                          328
  AAEL003100   salivary mucin                                                                              322
  AAEL005052   tubulin beta chain                                                                          312
  AAEL003107   N/A                                                                                         311
  AAEL006417   D7 protein, putative                                                                        309
  AAEL006833   succinyl-CoA synthetase small subunit, putative                                             308
  AAEL003600   34 kDa salivary protein, putative                                                           306
  AAEL004297   ATP-citrate synthase                                                                        302
  AAEL006721   2-oxoglutarate dehydrogenase                                                                297
  AAEL014452   acyl-coa dehydrogenase                                                                      296
  AAEL004500   eukaryotic translation elongation factor                                                    295
  AAEL008167   aspartate ammonia lyase                                                                     287
  AAEL010585   spermatogenesis associated factor                                                           285
  AAEL000793   venom allergen                                                                              284
  AAEL001194   fatty acid synthase                                                                         284
  AAEL007555   acyl-coa dehydrogenase                                                                      280
  AAEL009651   nascent polypeptide associated complex alpha subunit (nac alpha)                            270
  AAEL002764   dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase              269
  AAEL013613   pyruvate dehydrogenase                                                                      267
  AAEL002572   myosin regulatory light chain 2 (mlc-2)                                                     266
  AAEL007065   ADP-ribosylation factor, arf                                                                265
  AAEL006096   gelsolin precursor                                                                          263
  AAEL010464   glutamate dehydrogenase                                                                     262
  AAEL008192   40S ribosomal protein S3                                                                    239
  AAEL005931   6-phosphogluconate dehydrogenase                                                            237
  AAEL013904   3-hydroxyisobutyrate dehydrogenase                                                          234
  AAEL002841   3-hydroxyacyl-coa dehyrogenase                                                              233
  AAEL005798   ATP synthase subunit beta vacuolar                                                          231
  AAEL006834   glutamate semialdehyde dehydrogenase                                                        228
  AAEL007707   malate dehydrogenase                                                                        225
  AAEL013144   eukaryotic translation initiation factor 3 subunit I (eIF3i)                                221
  AAEL000726   fibrinogen and fibronectin                                                                  221
  AAEL004294   dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase                      208
  AAEL003694   N/A                                                                                         206
  AAEL002296   trifunctional enzyme beta subunit (tp-beta)                                                 203
  AAEL006040   coatomer                                                                                    201
  AAEL005084   tubulin beta chain                                                                          201
  AAEL004739   acyl-coa dehydrogenase                                                                      199
  AAEL007718   eukaryotic translation initiation factor 3 subunit B (eIF3b)                                195
  AAEL013353   profilin                                                                                    195
  AAEL003530   acidic ribosomal protein P1, putative                                                       190
  AAEL000392   maltase-like 1                                                                              189
  AAEL005422   pyrroline-5-carboxylate dehydrogenase                                                       189
  AAEL001588   glutamate carboxypeptidase                                                                  184
  AAEL008619   trypsin-like salivary secreted protein                                                      183
  AAEL003125   acyl-coa dehydrogenase                                                                      181
  AAEL008844   calcium-binding protein, putative                                                           181
  AAEL002693   venom allergen                                                                              178
  AAEL013359   DEAD box ATP-dependent RNA helicase                                                         176
  AAEL002309   thioredoxin peroxidase                                                                      174
  AAEL009029   aldehyde dehydrogenase                                                                      173
  AAEL006424   37 kDa salivary gland allergen Aed a 2 precursor (protein D7)(allergen Aed a 2)             170
  AAEL003634   hsp70-interacting protein, putative                                                         169
  AAEL008006   3-hydroxyacyl-coa dehyrogenase                                                              163
  AAEL007945   eukaryotic translation initiation factor 3 subunit H (eIF3h)                                161
  AAEL009902   eukaryotic translation initiation factor 3 subunit D (eIF3d)                                154
  AAEL001134   probable methylmalonate-semialdehyde dehydrogenase \[acylating\], mitochondrial precursor   151
  AAEL001668   enolase                                                                                     147
  AAEL011746   succinyl-coa synthetase beta chain                                                          147
  AAEL012359   nucleoside-diphosphate kinase NBR-A, putative                                               143
  AAEL003601   34 kDa secreted protein, putative                                                           140
  AAEL005069   ras-related protein Rab-1A, putative                                                        139
  AAEL009313   elongation factor -1 beta,delta                                                             138
  AAEL012746   chaperonin                                                                                  138
  AAEL013675   eukaryotic translation initiation factor                                                    136
  AAEL013625   40S ribosomal protein S5                                                                    135
  AAEL009747   40S ribosomal protein S18                                                                   134
  AAEL011756   aldehyde dehydrogenase                                                                      128
  AAEL001005   calreticulin                                                                                126
  AAEL000641   protein disulfide isomerase                                                                 126
  AAEL001218   alanyl-tRNA synthetase                                                                      126
  AAEL001128   AMP dependent coa ligase                                                                    126
  AAEL010143   isocitrate dehydrogenase                                                                    125
  AAEL006174   proteasome subunit beta type                                                                123
  AAEL012207   myosin light chain 1                                                                        122
  AAEL008848   ATP synthase gamma subunit                                                                  121
  AAEL000703   glycogen phosphorylase                                                                      121
  AAEL006634   acetyl-coa acetyltransferase, mitochondrial (acetoacetyl-coa thiolase)                      121
  AAEL003993   cyclohex-1-ene-1-carboxyl-CoA hydratase, putative                                           119
  AAEL005567   nucleosome assembly protein                                                                 117
  AAEL006085   methylenetetrahydrofolate dehydrogenase                                                     117
  AAEL008083   40S ribosomal protein SA                                                                    114
  AAEL004378   eukaryotic translation initiation factor 1A (eIF-1A)                                        114
  AAEL013069   receptor for activated protein kinase c (rack1)                                             113
  AAEL002504   ATP synthase delta chain, mitochondrial                                                     112
  AAEL004347   eukaryotic translation initiation factor 3 subunit M (eIF3m)                                111
  AAEL009617   eukaryotic translation initiation factor 3 subunit L (eIF3l)                                107
  AAEL012825   bifunctional purine biosynthesis protein                                                    107
  AAEL006928   dihydrolipoamide dehydrogenase                                                              106
  AAEL002833   cathepsin l                                                                                 106
  AAEL002334   eukaryotic translation initiation factor 3 subunit E (eIF3e)                                105
  AAEL009872   alanine aminotransferase                                                                    105
  AAEL011741   glutathione transferase                                                                     104
  AAEL007064   Gram-negative Binding Protein (GNBP) or beta-1 3-glucan binding protein                     104
  AAEL005269   ubiquinol-cytochrome c reductase complex core protein                                       103
  AAEL007033   pyrroline-5-carboxylate reductase                                                           103
  AAEL005407   annexin x                                                                                   102
  AAEL001331   mannose-1-phosphate guanyltransferase                                                       102

To confirm if D7 protein can directly interact with DENV2, we performed an enzyme-linked immunosorbent assay (ELISA) by binding a control MMP protein or recombinant D7 protein to a 96 well plate \[[@pntd.0004941.ref024]\]. Plates were then incubated with DENV2 16881 virions. Unbound proteins were then removed by washing each well with buffer. The degree of association between immobilized proteins and DENV2 virions was assessed using an antibody that recognized DENV followed by a secondary antibody conjugated to horse radish peroxidase. DENV2 16881 virions bound to D7 protein more readily than MMP protein. ([Fig 6A](#pntd.0004941.g006){ref-type="fig"}). Plates coated with D7 protein were then incubated with bovine serum albumin, DENV2 16881 virions, or recombinant DENV2 envelope protein. Unbound proteins were then removed by washing each well with buffer. The degree of association between D7 and the above proteins was assessed using an antibody recognizing DENV followed by a secondary antibody conjugated with horse radish peroxidase. We found that recombinant D7 interacted with both DENV2 16881 virions and recombinant DENV2 envelope protein ([Fig 6B](#pntd.0004941.g006){ref-type="fig"}).

![Recombinant D7 protein binds DENV2 virions and DENV2 envelope protein.\
(A) An enzyme-linked immunosorbent assay was developed by coating plates with control MMP protein or recombinant D7 protein and then measuring binding of DENV2 virions. (B) An enzyme-linked immunosorbent assay was developed by coating plates with recombinant D7 protein and then measuring binding of bovine serum albumin (BSA), DENV2 virions, and recombinant DENV2 envelope protein. Interactions were detected using antibodies against DENV2 envelope protein and a secondary antibody conjugated to horse radish peroxidase. Absorbance was detected at OD 450 nm. Student's t tests were performed to assess statistical significance between groups.](pntd.0004941.g006){#pntd.0004941.g006}

Discussion {#sec017}
==========

Hematophagous arthropod saliva contains a complex mixture of proteins with anti-hemostatic, anti-inflammatory, and immunomodulatory properties. Hematophagous arthropod saliva can also enhance transmission of arboviruses, although the exact mechanism and saliva proteins involved in this process are not known \[[@pntd.0004941.ref003]\]. Interestingly, individual saliva components can have inhibitory activities that prevent arbovirus infection \[[@pntd.0004941.ref019]\]. Here, we identified D7 protein in biochemical fractions of salivary gland extracts that inhibited DENV2 cell binding and/or infection in mouse embryonic fibroblasts and then determined if this activity could be recapitulated with recombinant D7 protein. We found that recombinant D7 protein prevented DENV2 cell binding and/or infection in two permissive cell types and prevented infection and dissemination in a mouse model. Additionally, two separate binding assays suggest that D7 protein can physically interact with DENV virions and envelope protein. These data support the previous observation that D7 protein vaccination enhanced mortality in a West Nile virus mouse model and suggest that D7 protein inhibits virus transmission \[[@pntd.0004941.ref020]\].

D7 proteins are some of the most abundant proteins expressed in the salivary glands of blood feeding *Diptera*. Long and short forms of D7 proteins exist in mosquitoes. Each of these proteins appear capable of binding either cysteinyl leukotrienes, and/or biogenic amines such as serotonin, histamine, and norepinephrine. These functions are predicted to antagonize the host's inflammatory response, and ability to vasoconstrict, induce platelet-aggregation, and induce a sense of pain--each critical to efficiently obtaining a blood meal \[[@pntd.0004941.ref021], [@pntd.0004941.ref022]\].

It is theoretically possible that the functions of D7 proteins are counter to the needs of arboviruses during transmission to a vertebrate host. D7 proteins bind multiple substrates and it is possible that they bind other proteins with lower affinity, which may limit virus-host interactions. Additionally, limiting the host inflammatory response may reduce influx or activation of target cells, such as Langerhans cells, monocytes, or macrophage. Our data support that D7 protein mediates its antiviral effect through direct protein-protein interaction *in vitro*, although it is possible that modulation of the inflammatory response also occurs *in vivo*.

D7 proteins are some of the most abundant and immunogenic proteins present in mosquito saliva \[[@pntd.0004941.ref025]\]. The presence of anti-D7 antibodies has been used as a marker of exposure to certain mosquito species \[[@pntd.0004941.ref026]--[@pntd.0004941.ref029]\]. Considering that individuals who are exposed to mosquitoes have high levels of anti-D7 antibodies, it is likely that these antibodies inhibit D7 protein function. In fact, the presence of anti-D7 antibodies has been linked to disease severity \[[@pntd.0004941.ref029]\]. Although anti-D7 antibodies may prevent efficient blood feeding by a mosquito, it may also enhance disease transmission and disease severity. Characterizing the complex interplay of virus-vector-host interactions will lead to the development of better models of pathogenesis, strategies to limit disease transmission and promote the development of therapeutics, and transmission-blocking vaccines.
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